{"id":96,"date":"2024-06-26T13:51:26","date_gmt":"2024-06-26T13:51:26","guid":{"rendered":"https:\/\/www.merckvaccines.com\/vaxneuvance\/?page_id=96"},"modified":"2025-12-22T11:02:01","modified_gmt":"2025-12-22T11:02:01","slug":"frequently-asked-questions","status":"publish","type":"page","link":"https:\/\/www.merckvaccines.com\/vaxneuvance\/frequently-asked-questions\/","title":{"rendered":"Frequently asked questions"},"content":{"rendered":"\n\n
<\/div>\"\"<\/picture>

Frequently asked questions about VAXNEUVANCE<\/strong><\/h1>

<\/p>

<\/div>
<\/div><\/div><\/div><\/div>
<\/div><\/div>\n\n\n\n\n
<\/div>\n\n\n\n\n
default-sum-open-background-color<\/div>
default-sum-close-background-color<\/div>
false<\/div>
default-sum-open-hover-color<\/div>
default-sum-open-focus-color<\/div>
default-sum-close-focus-color<\/div>
.default-sum-close-hover-color<\/div>

What are the Indications and Usage for VAXNEUVANCE\u00ae<\/sup> (Pneumococcal 15-valent<\/span> Conjugate Vaccine)?<\/strong><\/strong><\/h4><\/summary>
\n
<\/div>\n\n\n\n

VAXNEUVANCE is indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae <\/em>serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older.<\/p>\n<\/div><\/details><\/div>\n\n\n\n

default-sum-open-background-color<\/div>
default-sum-close-background-color<\/div>
false<\/div>
default-sum-open-hover-color<\/div>
default-sum-open-focus-color<\/div>
default-sum-close-focus-color<\/div>
.default-sum-close-hover-color<\/div>

What is the Select Safety Information for VAXNEUVANCE\u00ae<\/sup> (Pneumococcal 15-valent<\/span> Conjugate Vaccine)?<\/strong><\/h4><\/summary>
\n
<\/div>\n\n\n\n

Do not administer VAXNEUVANCE to individuals with a severe allergic reaction (eg, anaphylaxis) to any component of VAXNEUVANCE or to diphtheria toxoid.<\/p>\n\n\n\n

<\/div>\n\n\n\n

Some individuals with altered immunocompetence, including those receiving immunosuppressive therapy, may have a reduced immune response to VAXNEUVANCE.<\/p>\n\n\n\n

<\/div>\n\n\n\n

Apnea following intramuscular vaccination has been observed in some infants born prematurely. Vaccination of premature infants should be based on the infant\u2019s medical status and the potential benefits and possible risks.<\/p>\n\n\n\n

<\/div>\n\n\n\n

The most commonly reported solicited adverse reactions in children vaccinated at 2, 4, 6, and 12 through 15 months of age, provided as a range across the 4-dose series, were: irritability (57.3% to 63.4%), somnolence (24.2% to 47.5%), injection-site pain (25.9% to 40.3%), fever \u226538.0\u00b0C (13.3% to 20.4%), decreased appetite (14.1% to 19.0%), injection-site induration (13.2% to 15.4%), injection-site erythema (13.7% to 21.4%), and injection-site swelling (11.3% to 13.4%).<\/p>\n\n\n\n

<\/div>\n\n\n\n

The most commonly reported solicited adverse reactions in children 2 through 17 years of age vaccinated with a single dose were: injection-site pain (54.8%), myalgia (23.7%), injection-site swelling (20.9%), injection-site erythema (19.2%), fatigue (15.8%), headache (11.9%), and injection-site induration (6.8%).<\/p>\n\n\n\n

<\/div>\n\n\n\n

The reported solicited adverse reactions in children 7 through 11 months of age who received 3 doses of VAXNEUVANCE were: fever \u226538.0\u00b0C (21.9%), irritability (32.8%), injection-site erythema (28.1%), somnolence (21.9%), injection-site swelling (18.8%), injection-site pain (18.8%), injection-site induration (17.2%), decreased appetite (15.6%), and urticaria (1.6%).<\/p>\n\n\n\n

<\/div>\n\n\n\n

The reported solicited adverse reactions in children 12 through 23 months of age who received 2 doses of VAXNEUVANCE were: fever \u226538.0\u00b0C (11.3%), irritability (35.5%), injection-site pain (33.9%), somnolence (24.2%), decreased appetite (22.6%), injection-site erythema (21.0%), injection-site swelling (14.5%), and injection-site induration (8.1%).<\/p>\n\n\n\n

<\/div>\n\n\n\n

Vaccination with VAXNEUVANCE may not protect all vaccine recipients.<\/p>\n\n\n\n

<\/div>\n\n\n\n

Before administering VAXNEUVANCE, please read the<\/strong> accompanying<\/strong> Prescribing Information<\/strong><\/a>. The<\/strong> Patient Information<\/strong><\/a> also is available.<\/strong><\/p>\n<\/div><\/details><\/div>\n\n\n\n

default-sum-open-background-color<\/div>
default-sum-close-background-color<\/div>
false<\/div>
default-sum-open-hover-color<\/div>
default-sum-open-focus-color<\/div>
default-sum-close-focus-color<\/div>
.default-sum-close-hover-color<\/div>

What are the key effects of common IPD types?<\/strong><\/h4><\/summary>
\n
<\/div>\n\n\n\n

The key effects of common IPD types are pneumococcal meningitis and pneumococcal bacteremia.<\/p>\n\n\n\n

<\/div>\n\n\n\n

About 1 in 12 children die of pneumococcal meningitis.1<\/sup> Survivors may have lifelong disabilities, such as hearing loss or other neurological complications.1<\/sup><\/p>\n\n\n\n

<\/div>\n\n\n\n

Pneumococcal bacteremia is the most common type of IPD in children under 2 years of age.1,2,a<\/sup> About 1 in 30 affected children will die of it.1<\/sup><\/p>\n\n\n\n

<\/div>\n\n\n\n

a<\/sup> Without a known site of infection.2<\/sup><\/p>\n\n\n\n

<\/div>\n\n\n\n

IPD, invasive pneumococcal disease.<\/p>\n<\/div><\/details><\/div>\n\n\n\n

default-sum-open-background-color<\/div>
default-sum-close-background-color<\/div>
false<\/div>
default-sum-open-hover-color<\/div>
default-sum-open-focus-color<\/div>
default-sum-close-focus-color<\/div>
.default-sum-close-hover-color<\/div>

What is the recommended dosing for VAXNEUVANCE\u00ae<\/sup> (Pneumococcal 15-valent<\/span> Conjugate Vaccine)?<\/strong><\/h4><\/summary>
\n
<\/div>\n\n\n\n

VAXNEUVANCE is a suspension for injection (0.5 mL dose), supplied as a single-dose prefilled syringe. It is given as an intramuscular injection only.<\/p>\n\n\n\n

<\/div>\n\n\n\n

Administer VAXNEUVANCE as a 4-dose series at 2, 4, 6 and 12 through 15 months of age (and at least 2 months after the third dose). The first dose may be given as early as 6 weeks of age.<\/p>\n\n\n\n

<\/div>\n\n\n\n

Get resources<\/a> for managing VAXNEUVANCE <\/strong>at your practice.<\/p>\n<\/div><\/details><\/div>\n\n\n\n

default-sum-open-background-color<\/div>
default-sum-close-background-color<\/div>
false<\/div>
default-sum-open-hover-color<\/div>
default-sum-open-focus-color<\/div>
default-sum-close-focus-color<\/div>
.default-sum-close-hover-color<\/div>

Is VAXNEUVANCE\u00ae<\/sup> (Pneumococcal 15-valent<\/span> Conjugate Vaccine) available for children through the Vaccines for Children (VFC) Program?<\/strong><\/h4><\/summary>
\n
<\/div>\n\n\n\n

Yes, VAXNEUVANCE is available through the VFC Program.3<\/sup><\/p>\n<\/div><\/details><\/div>\n\n\n\n

default-sum-open-background-color<\/div>
default-sum-close-background-color<\/div>
false<\/div>
default-sum-open-hover-color<\/div>
default-sum-open-focus-color<\/div>
default-sum-close-focus-color<\/div>
.default-sum-close-hover-color<\/div>

What are the CDC guidelines for use of VAXNEUVANCE\u00ae<\/sup> (Pneumococcal 15-valent<\/span> Conjugate Vaccine) in pediatric patients?<\/strong><\/h4><\/summary>
\n
<\/div>\n\n\n\n

The CDC recommends the use of VAXNEUVANCE as an option for routine vaccination in infants and children, as well as vaccination in children with certain medical conditions.4<\/sup><\/p>\n\n\n\n

<\/div>\n\n\n\n

Learn more about recommendations<\/a> for VAXNEUVANCE.<\/p>\n\n\n\n

<\/div>\n\n\n\n

CDC, Centers for Disease Control and Prevention.<\/p>\n<\/div><\/details><\/div>\n\n\n\n

default-sum-open-background-color<\/div>
default-sum-close-background-color<\/div>
false<\/div>
default-sum-open-hover-color<\/div>
default-sum-open-focus-color<\/div>
default-sum-close-focus-color<\/div>
.default-sum-close-hover-color<\/div>

What is the catch-up dosing schedule for VAXNEUVANCE\u00ae<\/sup> (Pneumococcal 15-valent<\/span> Conjugate Vaccine) in pediatric patients?<\/strong><\/h4><\/summary>
\n
<\/div>\n\n\n\n

Infants 7 months through 11 months of age should be administered 3 doses of VAXNEUVANCE. The first 2 doses are given at least 4 weeks apart and the 3rd dose is given after the one-year birthday, separated from the second dose by at least 2 months.<\/p>\n\n\n\n

<\/div>\n\n\n\n

Toddlers 12 months through 23 months of age should be administered 2 doses of VAXNEUVANCE. These 2 doses should be given at least 2 months apart.<\/p>\n\n\n\n

<\/div>\n\n\n\n

Children and adolescents 2 years through 17 years of age who have received an incomplete series of another pneumococcal conjugate vaccine should be administered a single dose of VAXNEUVANCE. At least 2 months should elapse between receipt of the last dose of another pneumococcal conjugate vaccine and administration of VAXNEUVANCE.<\/p>\n\n\n\n

<\/div>\n\n\n\n

See guidance on pediatric dosage and administration<\/a> of VAXNEUVANCE.<\/p>\n<\/div><\/details><\/div>\n\n\n\n

default-sum-open-background-color<\/div>
default-sum-close-background-color<\/div>
false<\/div>
default-sum-open-hover-color<\/div>
default-sum-open-focus-color<\/div>
default-sum-close-focus-color<\/div>
.default-sum-close-hover-color<\/div>

What is the CPT Code for VAXNEUVANCE\u00ae (Pneumococcal 15-valent<\/span> Conjugate Vaccine)?<\/strong><\/h4><\/summary>
\n
<\/div>\n\n\n\n

The CPT Code for VAXNEUVANCE is 90671.5<\/sup><\/p>\n\n\n\n

<\/div>\n\n\n\n

The information provided here is compiled from sources believed to be accurate, but Merck makes no representation that it is accurate. Consult the relevant manual and\/or other guidelines for a description of each code to determine the appropriateness of a particular code and for information on additional codes. This information is subject to change. Merck cautions that payer coding requirements vary and can frequently change, so it\u2019s important to regularly check with each payer as to payer-specific requirements.<\/p>\n\n\n\n

<\/div>\n\n\n\n

You are solely responsible for determining the appropriate codes and for any action you take in billing. The information provided here is not intended to be definitive or exhaustive, and is not intended to replace the guidance of a qualified professional advisor. Merck makes no warranties or guarantees, expressed or implied, concerning the accuracy or appropriateness of this information for your particular use given the frequent changes in public and private payer billing. The use of this information does not guarantee payment or that any payment received will cover your costs. Diagnosis codes should be selected only by a health care professional.<\/p>\n\n\n\n

<\/div>\n\n\n\n

CPT, Current Procedural Terminology.<\/p>\n\n\n\n

<\/div>\n\n\n\n

CPT is a registered trademark of the American Medical Association.<\/p>\n<\/div><\/details><\/div>\n\n\n\n

default-sum-open-background-color<\/div>
default-sum-close-background-color<\/div>
false<\/div>
default-sum-open-hover-color<\/div>
default-sum-open-focus-color<\/div>
default-sum-close-focus-color<\/div>
.default-sum-close-hover-color<\/div>

When was VAXNEUVANCE\u00ae<\/sup> (Pneumococcal 15-valent<\/span> Conjugate Vaccine) first approved for use by the FDA?<\/strong><\/h4><\/summary>
\n
<\/div>\n\n\n\n

VAXNEUVANCE was initially approved by the FDA in July 2021. VAXNEUVANCE received approval for pediatrics in June 2022.<\/p>\n\n\n\n

<\/div>\n\n\n\n

FDA, Food and Drug Administration.<\/p>\n<\/div><\/details><\/div>\n\n\n\n

default-sum-open-background-color<\/div>
default-sum-close-background-color<\/div>
false<\/div>
default-sum-open-hover-color<\/div>
default-sum-open-focus-color<\/div>
default-sum-close-focus-color<\/div>
.default-sum-close-hover-color<\/div>

Can VAXNEUVANCE\u00ae<\/sup> (Pneumococcal 15-valent<\/span> Conjugate Vaccine) be administered concurrently with other pediatric vaccines in children?<\/strong><\/h4><\/summary>
\n
<\/div>\n\n\n\n

Yes, VAXNEUVANCE can be given with other pediatric vaccines (including Pentacel<\/em>, RECOMBIVAX HB\u00ae<\/sup>, RotaTeq\u00ae<\/sup>, M-M-R\u00ae<\/sup>II<\/sub>, VAQTA\u00ae<\/sup>, VARIVAX\u00ae<\/sup>, and Hiberix<\/em>).<\/p>\n\n\n\n

<\/div>\n\n\n\n

Brands mentioned are trademarks of their respective owners.<\/p>\n<\/div><\/details><\/div>\n\n\n\n

default-sum-open-background-color<\/div>
default-sum-close-background-color<\/div>
false<\/div>
default-sum-open-hover-color<\/div>
default-sum-open-focus-color<\/div>
default-sum-close-focus-color<\/div>
.default-sum-close-hover-color<\/div>

What are the most common adverse reactions for VAXNEUVANCE\u00ae<\/sup> (Pneumococcal 15-valent<\/span> Conjugate Vaccine) for pediatric patients?<\/strong><\/h4><\/summary>
\n
<\/div>\n\n\n\n

The most commonly reported solicited adverse reactions in children vaccinated with a 4-dose series at 2, 4, 6, and 12 through 15 months of age, provided as a range across the series, were: irritability (57.3% to 63.4%), somnolence (24.2% to 47.5%), injection-site pain (25.9% to 40.3%), fever \u226538.0\u00b0C (13.3% to 20.4%), decreased appetite (14.1% to 19.0%), injection-site induration (13.2% to 15.4%), injection-site erythema (13.7% to 21.4%) and injection-site swelling (11.3% to 13.4%).<\/p>\n\n\n\n

<\/div>\n\n\n\n

The most commonly reported solicited adverse reactions in children and adolescents 2 through 17 years of age vaccinated with a single dose were: injection-site pain (54.8%), myalgia (23.7%), injection-site swelling (20.9%), injection-site erythema (19.2%), fatigue (15.8%), headache (11.9%) and injection-site induration (6.8%).<\/p>\n\n\n\n

<\/div>\n\n\n\n

Among participants 7 through 11 months of age who received 3 doses of VAXNEUVANCE (N=64) or Prevnar 13 (N=64), the percentage of participants reporting solicited local and systemic adverse reactions that occurred within 14 days following any dose (VAXNEUVANCE participants vs. Prevnar 13 participants) were: fever \u226538.0\u00b0C (21.9% vs. 14.1%), irritability (32.8% vs. 43.8%), injection-site erythema (28.1% vs. 34.4%), somnolence (21.9% vs. 15.6%), injection-site swelling (18.8% vs. 15.6%), injection-site pain (18.8% vs. 7.8%), injection-site induration (17.2% vs. 14.1%), decreased appetite (15.6% vs. 18.8%) and urticaria (1.6% vs. 4.7%).<\/p>\n\n\n\n

<\/div>\n\n\n\n

Among participants 12 through 23 months of age who received 2 doses of VAXNEUVANCE (N=62) or Prevnar 13 (N=64), the percentage of participants reporting solicited local and systemic adverse reactions that occurred within 14 days following any dose (VAXNEUVANCE participants vs. Prevnar 13 participants) were: fever \u226538.0\u00b0C (11.3% vs. 9.4%), irritability (35.5% vs. 21.9%), injection-site pain (33.9% vs. 23.4%), somnolence (24.2% vs. 17.2%), decreased appetite (22.6% vs. 18.8%), injection-site erythema (21.0% vs. 21.9%), injection-site swelling (14.5% vs. 12.5%) and injection-site induration (8.1% vs. 9.4%).<\/p>\n\n\n\n

<\/div>\n\n\n\n

View safety and tolerability<\/a> data for VAXNEUVANCE.<\/p>\n<\/div><\/details><\/div>\n\n\n\n

default-sum-open-background-color<\/div>
default-sum-close-background-color<\/div>
false<\/div>
default-sum-open-hover-color<\/div>
default-sum-open-focus-color<\/div>
default-sum-close-focus-color<\/div>
.default-sum-close-hover-color<\/div>

What are the contraindications for VAXNEUVANCE\u00ae<\/sup> (Pneumococcal 15-valent<\/span> Conjugate Vaccine) for pediatric patients?<\/strong><\/h4><\/summary>
\n
<\/div>\n\n\n\n

Do not administer VAXNEUVANCE to individuals with a severe allergic reaction (eg, anaphylaxis) to any component of VAXNEUVANCE or to diphtheria toxoid.<\/p>\n\n\n\n

<\/div>\n\n\n\n

View safety and tolerability<\/a> data for VAXNEUVANCE.<\/p>\n<\/div><\/details><\/div>\n\n\n\n

default-sum-open-background-color<\/div>
default-sum-close-background-color<\/div>
false<\/div>
default-sum-open-hover-color<\/div>
default-sum-open-focus-color<\/div>
default-sum-close-focus-color<\/div>
.default-sum-close-hover-color<\/div>

How is VAXNEUVANCE\u00ae<\/sup> (Pneumococcal 15-valent<\/span> Conjugate Vaccine) administered?<\/strong><\/h4><\/summary>
\n
<\/div>\n\n\n\n

To administer VAXNEUVANCE, hold the prefilled syringe horizontally and shake vigorously immediately prior to use to obtain an opalescent suspension. Do not use the vaccine if it cannot be resuspended. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use if particulate matter or discoloration is observed.<\/p>\n\n\n\n

<\/div>\n\n\n\n

See guidance on pediatric dosage and administration<\/a> of VAXNEUVANCE.<\/p>\n<\/div><\/details><\/div>\n\n\n\n

default-sum-open-background-color<\/div>
default-sum-close-background-color<\/div>
false<\/div>
default-sum-open-hover-color<\/div>
default-sum-open-focus-color<\/div>
default-sum-close-focus-color<\/div>
.default-sum-close-hover-color<\/div>

What are the warnings and precautions for VAXNEUVANCE\u00ae<\/sup> (Pneumococcal 15-valent<\/span> Conjugate Vaccine) for pediatric patients?<\/strong><\/h4><\/summary>
\n
<\/div>\n\n\n\n

Appropriate medical treatment to manage allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of VAXNEUVANCE.<\/p>\n\n\n\n

<\/div>\n\n\n\n

Some individuals with altered immunocompetence, including those receiving immunosuppressive therapy, may have a reduced immune response to VAXNEUVANCE.<\/p>\n\n\n\n

<\/div>\n\n\n\n

Apnea following intramuscular vaccination has been observed in some infants born prematurely. A decision about when to administer VAXNEUVANCE to infants born prematurely should be based on consideration of the individual infant\u2019s medical status and the potential benefits and possible risks of vaccination.<\/p>\n\n\n\n

<\/div>\n\n\n\n

View safety and tolerability<\/a> data for VAXNEUVANCE.<\/p>\n<\/div><\/details><\/div>\n\n\n\n

default-sum-open-background-color<\/div>
default-sum-close-background-color<\/div>
false<\/div>
default-sum-open-hover-color<\/div>
default-sum-open-focus-color<\/div>
default-sum-close-focus-color<\/div>
.default-sum-close-hover-color<\/div>

How do I report a suspected adverse event?<\/strong><\/h4><\/summary>
\n
<\/div>\n\n\n\n

To report a suspected adverse reaction, contact Merck at 1-877-888-4231<\/span> or VAERS at 1-800-822-7967<\/span> or www.vaers.hhs.gov<\/a>.<\/strong><\/p>\n<\/div><\/details><\/div>\n\n\n\n

default-sum-open-background-color<\/div>
default-sum-close-background-color<\/div>
false<\/div>
default-sum-open-hover-color<\/div>
default-sum-open-focus-color<\/div>
default-sum-close-focus-color<\/div>
.default-sum-close-hover-color<\/div>

How can I order VAXNEUVANCE\u00ae<\/sup> (Pneumococcal 15-valent<\/span> Conjugate Vaccine) for my practice?<\/strong><\/h4><\/summary>
\n
<\/div>\n\n\n\n

VAXNEUVANCE can be ordered via ordering.merckvaccines.com<\/strong><\/a>, by calling into the Merck Vaccines Customer Care line 877.VAX.MERCK (877.829.6372), or through your preferred wholesaler\/distributor. For a list of Merck authorized distributors please go to Authorized distributors \u2013 Merck.com<\/a><\/strong>.<\/p>\n<\/div><\/details><\/div>\n\n\n\n

default-sum-open-background-color<\/div>
default-sum-close-background-color<\/div>
false<\/div>
default-sum-open-hover-color<\/div>
default-sum-open-focus-color<\/div>
default-sum-close-focus-color<\/div>
.default-sum-close-hover-color<\/div>

What pneumococcal serotypes are contained in VAXNEUVANCE\u00ae<\/sup> (Pneumococcal 15-valent<\/span> Conjugate Vaccine)?<\/strong><\/h4><\/summary>
\n
<\/div>\n\n\n\n

VAXNEUVANCE is a sterile suspension of purified capsular polysaccharides from Streptococcus pneumoniae<\/em> serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F.<\/p>\n\n\n\n

<\/div>\n\n\n\n

See immunogenicity<\/a> data for VAXNEUVANCE.<\/p>\n<\/div><\/details><\/div>\n\n\n\n

default-sum-open-background-color<\/div>
default-sum-close-background-color<\/div>
false<\/div>
default-sum-open-hover-color<\/div>
default-sum-open-focus-color<\/div>
default-sum-close-focus-color<\/div>
.default-sum-close-hover-color<\/div>

What are the storage requirements for VAXNEUVANCE\u00ae<\/sup> (Pneumococcal 15-valent<\/span> Conjugate Vaccine)?<\/strong><\/h4><\/summary>
\n
<\/div>\n\n\n\n

Store refrigerated at 2\u00b0C to 8\u00b0C (36\u00b0F to 46\u00b0F).<\/p>\n\n\n\n

<\/div>\n\n\n\n

Do not freeze. Protect from light.<\/p>\n\n\n\n

<\/div>\n\n\n\n

If you have specific storage and handling questions, please contact the Merck Vaccines customer center at 877.VAX.MERCK<\/span> (877.829.6372)<\/span>. For general questions concerning the proper storage and handling of Merck vaccines, please contact the Merck Vaccine Customer Help Line at 800.MERCK.90 (800.637.2590), Monday through Friday, 8:00 AM \u2013 7:00 PM ET.<\/p>\n\n\n\n

<\/div>\n\n\n\n

Learn how VAXNEUVANCE is supplied<\/a>.<\/p>\n<\/div><\/details><\/div>\n\n\n\n

default-sum-open-background-color<\/div>
default-sum-close-background-color<\/div>
false<\/div>
default-sum-open-hover-color<\/div>
default-sum-open-focus-color<\/div>
default-sum-close-focus-color<\/div>
.default-sum-close-hover-color<\/div>

How do I report a suspected product quality complaint?<\/strong><\/h4><\/summary>
\n
<\/div>\n\n\n\n

To report a suspected product quality complaint, contact Merck at 1-877-888-4231<\/span>.<\/p>\n<\/div><\/details><\/div>\n\n\n\n

default-sum-open-background-color<\/div>
default-sum-close-background-color<\/div>
false<\/div>
default-sum-open-hover-color<\/div>
default-sum-open-focus-color<\/div>
default-sum-close-focus-color<\/div>
.default-sum-close-hover-color<\/div>

Can VAXNEUVANCE\u00ae<\/sup><\/strong> (Pneumococcal 15-valent Conjugate Vaccine) be used in other age groups?<\/strong><\/h4><\/summary>
\n
<\/div>\n\n\n\n

Yes, please see Prescribing Information<\/a> for more information.<\/p>\n<\/div><\/details><\/div>\n\n\n\n

<\/div>\n\n\n\n\n

References:<\/strong><\/h2><\/div>\n\n\n\n\n
\n
    \n
  1. Centers for Disease Control and Prevention (CDC). Pneumococcal Disease Symptoms and Complications. Last reviewed February 6, 2024. Accessed October 10, 2025. https:\/\/www.cdc.gov\/pneumococcal\/signs-symptoms\/index.html<\/span><\/li>\n\n\n\n
  2. Gierke R, Wodi P, Kobayashi M. Epidemiology and Prevention of Vaccine-Preventable Diseases <\/em>(Pink Book). 14th edition. Chapter 17: Pneumococcal disease. Centers for Disease Control and Prevention. Last reviewed August 2021. Accessed May 16, 2025. https:\/\/www.cdc.gov\/pinkbook\/hcp\/table-of-contents\/chapter-17-pneumococcal-disease.html<\/span><\/li>\n\n\n\n
  3. Centers for Disease Control and Prevention (CDC). VFC. CDC Vaccine Price List. Updated October 6, 2025. Accessed October 10, 2025. https:\/\/www.cdc.gov\/vaccines-for-children\/php\/awardees\/current-cdc-vaccine-price-list.html<\/li>\n\n\n\n
  4. Centers for Disease Control and Prevention. Recommended child and adolescent immunization schedule for ages 18 years or younger, United States, 2025. Revised October 7, 2025. Accessed October 12, 2025. https:\/\/www.cdc.gov\/vaccines\/hcp\/imz-schedules\/downloads\/child\/0-18yrs-child-combined-schedule.pdf<\/li>\n\n\n\n
  5. Immunization Information Systems (IIS): CPT codes mapped to CVX codes. Centers for Disease Control and Prevention. Last reviewed September 18, 2025. Accessed October 1, 2025. https:\/\/www2a.cdc.gov\/vaccines\/iis\/iisstandards\/vaccines.asp?rpt=cpt<\/span><\/li>\n<\/ol>\n<\/div>\n\n\n\n\n
    ExternalSitePopup<\/span><\/div>
    <\/i><\/a>

    By clicking on this link, you will be leaving Merck Vaccines.<\/h2><\/div>
    <\/div>
    Cancel<\/a><\/div>
    Proceed<\/a><\/div><\/div><\/div><\/div>
    Cancel<\/a><\/div>
    Proceed<\/a><\/div><\/div><\/div><\/div><\/div><\/div><\/div>\n\n\n\n
    vaerspopup<\/span><\/div>
    <\/i><\/a>

    By clicking on this link, you will be leaving this site.<\/strong><\/h2><\/div>
    \n\n

    \n\n<\/p>\n\n

    This link will take you to a site outside Merck & Co., Inc.<\/p>\n\n\n

    <\/div>\n\n\n

    Merck does not review or control the content of any non-Merck site. Merck does not endorse and is not responsible for the accuracy, content, practices, or standards of any non-Merck site.
    <\/p>\n\n

    \n\n<\/p>\n<\/div>

    Cancel<\/a><\/div>
    Proceed<\/a><\/div><\/div><\/div><\/div>
    Cancel<\/a><\/div>
    Proceed<\/a><\/div><\/div><\/div><\/div><\/div><\/div><\/div>\n\n\n\n
    authorizedpopup<\/span><\/div>
    <\/i><\/a>

    By clicking on this link, you will be leaving this site.<\/strong><\/h2><\/div>
    \n

    \n\n<\/p>\n\n

    This link will take you to a site outside Merck & Co., Inc.<\/p>\n\n\n

    <\/div>\n\n\n

    Merck does not review or control the content of any non-Merck site. Merck does not endorse and is not responsible for the accuracy, content, practices, or standards of any non-Merck site.
    <\/p>\n\n

    \n\n<\/p>\n<\/div>

    Cancel<\/a><\/div>
    Proceed<\/a><\/div><\/div><\/div><\/div>
    Cancel<\/a><\/div>
    Proceed<\/a><\/div><\/div><\/div><\/div><\/div><\/div><\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":708,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_trash_the_other_posts":false,"editor_notices":[],"footnotes":""},"ga4_page_audience":[1166],"ga4_page_birn_id":[],"ga4_page_branding":[227],"ga4_page_businessunit":[235],"ga4_page_campaign":[],"ga4_page_content_purpose":[274],"ga4_page_customer_journey_stage":[295],"ga4_page_customer_specialty":[359],"ga4_page_experience":[],"ga4_page_indication":[1215],"ga4_page_material_intent":[575],"ga4_page_product":[777],"ga4_page_region":[1025],"ga4_page_therapeuticarea":[1120],"class_list":["post-96","page","type-page","status-publish"],"yoast_head":"\nFAQs About VAXNEUVANCE\u00ae (Pneumococcal 15-valent Conjugate Vaccine) for Patients<\/title>\n<meta name=\"description\" content=\"View frequently asked questions about VAXNEUVANCE\u00ae (Pneumococcal 15-valent Conjugate Vaccine) for appropriate patients, including information on dosing and CDC recommendations.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.merckvaccines.com\/vaxneuvance\/frequently-asked-questions\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FAQs About VAXNEUVANCE\u00ae (Pneumococcal 15-valent Conjugate Vaccine) for Patients\" \/>\n<meta property=\"og:description\" content=\"View frequently asked questions about VAXNEUVANCE\u00ae (Pneumococcal 15-valent Conjugate Vaccine) for appropriate patients, including information on dosing and CDC recommendations.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.merckvaccines.com\/vaxneuvance\/frequently-asked-questions\/\" \/>\n<meta property=\"og:site_name\" content=\"vaxneuvance-pediatric-mv\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-22T11:02:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.merckvaccines.com\/vaxneuvance\/wp-content\/uploads\/sites\/173\/2025\/12\/FAQ_Desktop.png?w=1488\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"11 minutes\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FAQs About VAXNEUVANCE\u00ae (Pneumococcal 15-valent Conjugate Vaccine) for Patients","description":"View frequently asked questions about VAXNEUVANCE\u00ae (Pneumococcal 15-valent Conjugate Vaccine) for appropriate patients, including information on dosing and CDC recommendations.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.merckvaccines.com\/vaxneuvance\/frequently-asked-questions\/","og_locale":"en_US","og_type":"article","og_title":"FAQs About VAXNEUVANCE\u00ae (Pneumococcal 15-valent Conjugate Vaccine) for Patients","og_description":"View frequently asked questions about VAXNEUVANCE\u00ae (Pneumococcal 15-valent Conjugate Vaccine) for appropriate patients, including information on dosing and CDC recommendations.","og_url":"https:\/\/www.merckvaccines.com\/vaxneuvance\/frequently-asked-questions\/","og_site_name":"vaxneuvance-pediatric-mv","article_modified_time":"2025-12-22T11:02:01+00:00","og_image":[{"url":"https:\/\/www.merckvaccines.com\/vaxneuvance\/wp-content\/uploads\/sites\/173\/2025\/12\/FAQ_Desktop.png?w=1488"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.merckvaccines.com\/vaxneuvance\/frequently-asked-questions\/","url":"https:\/\/www.merckvaccines.com\/vaxneuvance\/frequently-asked-questions\/","name":"FAQs About VAXNEUVANCE\u00ae (Pneumococcal 15-valent Conjugate Vaccine) for Patients","isPartOf":{"@id":"https:\/\/www.merckvaccines.com\/vaxneuvance\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.merckvaccines.com\/vaxneuvance\/frequently-asked-questions\/#primaryimage"},"image":{"@id":"https:\/\/www.merckvaccines.com\/vaxneuvance\/frequently-asked-questions\/#primaryimage"},"thumbnailUrl":"https:\/\/www.merckvaccines.com\/vaxneuvance\/wp-content\/uploads\/sites\/173\/2025\/12\/FAQ_Desktop.png?w=1488","datePublished":"2024-06-26T13:51:26+00:00","dateModified":"2025-12-22T11:02:01+00:00","description":"View frequently asked questions about VAXNEUVANCE\u00ae (Pneumococcal 15-valent Conjugate Vaccine) for appropriate patients, including information on dosing and CDC recommendations.","breadcrumb":{"@id":"https:\/\/www.merckvaccines.com\/vaxneuvance\/frequently-asked-questions\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.merckvaccines.com\/vaxneuvance\/frequently-asked-questions\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.merckvaccines.com\/vaxneuvance\/frequently-asked-questions\/#primaryimage","url":"https:\/\/www.merckvaccines.com\/vaxneuvance\/wp-content\/uploads\/sites\/173\/2025\/12\/FAQ_Desktop.png","contentUrl":"https:\/\/www.merckvaccines.com\/vaxneuvance\/wp-content\/uploads\/sites\/173\/2025\/12\/FAQ_Desktop.png","width":1718,"height":417},{"@type":"BreadcrumbList","@id":"https:\/\/www.merckvaccines.com\/vaxneuvance\/frequently-asked-questions\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.merckvaccines.com\/vaxneuvance\/"},{"@type":"ListItem","position":2,"name":"Frequently asked questions"}]},{"@type":"WebSite","@id":"https:\/\/www.merckvaccines.com\/vaxneuvance\/#website","url":"https:\/\/www.merckvaccines.com\/vaxneuvance\/","name":"vaxneuvance-pediatric-mv","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.merckvaccines.com\/vaxneuvance\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"}]}},"acf":[],"_links":{"self":[{"href":"https:\/\/www.merckvaccines.com\/vaxneuvance\/wp-json\/wp\/v2\/pages\/96","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.merckvaccines.com\/vaxneuvance\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.merckvaccines.com\/vaxneuvance\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.merckvaccines.com\/vaxneuvance\/wp-json\/wp\/v2\/users\/708"}],"replies":[{"embeddable":true,"href":"https:\/\/www.merckvaccines.com\/vaxneuvance\/wp-json\/wp\/v2\/comments?post=96"}],"version-history":[{"count":66,"href":"https:\/\/www.merckvaccines.com\/vaxneuvance\/wp-json\/wp\/v2\/pages\/96\/revisions"}],"predecessor-version":[{"id":2913,"href":"https:\/\/www.merckvaccines.com\/vaxneuvance\/wp-json\/wp\/v2\/pages\/96\/revisions\/2913"}],"wp:attachment":[{"href":"https:\/\/www.merckvaccines.com\/vaxneuvance\/wp-json\/wp\/v2\/media?parent=96"}],"wp:term":[{"taxonomy":"ga4_page_audience","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/vaxneuvance\/wp-json\/wp\/v2\/ga4_page_audience?post=96"},{"taxonomy":"ga4_page_birn_id","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/vaxneuvance\/wp-json\/wp\/v2\/ga4_page_birn_id?post=96"},{"taxonomy":"ga4_page_branding","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/vaxneuvance\/wp-json\/wp\/v2\/ga4_page_branding?post=96"},{"taxonomy":"ga4_page_businessunit","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/vaxneuvance\/wp-json\/wp\/v2\/ga4_page_businessunit?post=96"},{"taxonomy":"ga4_page_campaign","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/vaxneuvance\/wp-json\/wp\/v2\/ga4_page_campaign?post=96"},{"taxonomy":"ga4_page_content_purpose","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/vaxneuvance\/wp-json\/wp\/v2\/ga4_page_content_purpose?post=96"},{"taxonomy":"ga4_page_customer_journey_stage","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/vaxneuvance\/wp-json\/wp\/v2\/ga4_page_customer_journey_stage?post=96"},{"taxonomy":"ga4_page_customer_specialty","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/vaxneuvance\/wp-json\/wp\/v2\/ga4_page_customer_specialty?post=96"},{"taxonomy":"ga4_page_experience","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/vaxneuvance\/wp-json\/wp\/v2\/ga4_page_experience?post=96"},{"taxonomy":"ga4_page_indication","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/vaxneuvance\/wp-json\/wp\/v2\/ga4_page_indication?post=96"},{"taxonomy":"ga4_page_material_intent","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/vaxneuvance\/wp-json\/wp\/v2\/ga4_page_material_intent?post=96"},{"taxonomy":"ga4_page_product","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/vaxneuvance\/wp-json\/wp\/v2\/ga4_page_product?post=96"},{"taxonomy":"ga4_page_region","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/vaxneuvance\/wp-json\/wp\/v2\/ga4_page_region?post=96"},{"taxonomy":"ga4_page_therapeuticarea","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/vaxneuvance\/wp-json\/wp\/v2\/ga4_page_therapeuticarea?post=96"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}